PCM
RNAC icon

Penserra Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Penserra Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-88
Closed -$10K – 1522
2021
Q3 		$10K Buy
88
+2
+2% +$242 ﹤0.01% 1360
2021
Q2 		$10K Buy
86
+4
+5% +$476 ﹤0.01% 1273
2021
Q1 		$11K Sell
82
-1
-1% -$124 ﹤0.01% 1027
2020
Q4 		$7K Buy
+83
New +$7.2K ﹤0.01% 962

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Penserra Capital Management's RNAC Position: Q4 2021 in Review

Penserra Capital Management sold out of Cartesian Therapeutics (RNAC) in Q4 2021, closing a stake of 88 shares — an estimated $10K sold.

Penserra Capital Management first reported a position in RNAC in Q4 2020 and held it in 4 quarters. The position peaked at $11K in Q1 2021. 106 funds tracked by Wall St. Rank hold RNAC as of Q4 2021.

  • Penserra Capital Management reported no remaining Cartesian Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 88 Cartesian Therapeutics shares in Q4 2021, an estimated $10K.
  • Penserra Capital Management first reported a position in Cartesian Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Cartesian Therapeutics position peaked at $11K in Q1 2021.
  • 106 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.